000112076 001__ 112076 000112076 005__ 20240319081001.0 000112076 0247_ $$2doi$$a10.1016/j.bcp.2022.114992 000112076 0248_ $$2sideral$$a127937 000112076 037__ $$aART-2022-127937 000112076 041__ $$aeng 000112076 100__ $$aAkesolo, Olaia 000112076 245__ $$aToll-like receptors: New targets for multiple myeloma treatment? 000112076 260__ $$c2022 000112076 5060_ $$aAccess copy available to the general public$$fUnrestricted 000112076 5203_ $$aDespite recent biomedical improvements in treating multiple myeloma, this disease still remains incurable. Toll-like receptors (TLRs) are key immune receptors that recognize conserved molecular patterns expressed by pathogens and damaged cells. Activation of TLRs can induce several effects including inflammatory responses, modulation of cell cycle, apoptosis, or regulation of cell metabolism. In multiple myeloma there is a dysregulated signalling of TLRs due to an abnormal presence of certain pathogens and release of molecules from damaged cells. Thus, TLRs could be critical players for tumour microenvironment and multiple myeloma progression. This haematological malignancy is characterized by a high percentage of recurrences, where many patients can develop residual drug-resistant malignant cells. Strategic targeting of TLRs might result in novel therapeutic combinations that improve the response to current treatments, reducing relapses. This review examines the potential of TLRs as targets for the treatment of multiple myeloma, making a particular emphasis on their therapeutic applications. 000112076 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-20R$$9info:eu-repo/grantAgreement/ES/MECD/FPU17-02586$$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-105128RB-I00 000112076 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000112076 590__ $$a5.8$$b2022 000112076 592__ $$a1.329$$b2022 000112076 591__ $$aPHARMACOLOGY & PHARMACY$$b39 / 278 = 0.14$$c2022$$dQ1$$eT1 000112076 593__ $$aPharmacology$$c2022$$dQ1 000112076 593__ $$aBiochemistry$$c2022$$dQ1 000112076 594__ $$a9.8$$b2022 000112076 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000112076 700__ $$0(orcid)0000-0002-8467-0356$$aBuey, Berta$$uUniversidad de Zaragoza 000112076 700__ $$aBeltrán-Visiedo, Manuel$$uUniversidad de Zaragoza 000112076 700__ $$aGiraldos, David$$uUniversidad de Zaragoza 000112076 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo, Isabel$$uUniversidad de Zaragoza 000112076 700__ $$0(orcid)0000-0002-5797-3909$$aLatorre, Eva$$uUniversidad de Zaragoza 000112076 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología 000112076 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000112076 773__ $$g199 (2022), 114992 [12 pp.]$$pBiochem. pharmacol.$$tBiochemical Pharmacology$$x0006-2952 000112076 8564_ $$s2479786$$uhttps://zaguan.unizar.es/record/112076/files/texto_completo.pdf$$yVersión publicada 000112076 8564_ $$s2578578$$uhttps://zaguan.unizar.es/record/112076/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000112076 909CO $$ooai:zaguan.unizar.es:112076$$particulos$$pdriver 000112076 951__ $$a2024-03-18-14:08:48 000112076 980__ $$aARTICLE